Concepedia

Michael Bultman

MB

Statistics

Publications

8

Citations

231

H-Index

8

Active since

2008

Affiliations

Bristol-Myers Squibb (United States)(Current)

Memorial Sloan Kettering Cancer Center

Michael Bultman is an author at Bristol-Myers Squibb (United States) specializing in synthetic medicinal chemistry, pharmacy, and medicinal chemistry.

ORCID

Publications per year

2008–2019

8

Publications

8

Scalable Synthesis of the Potent HIV Inhibitor BMS‐986001 by Non‐Enzymatic Dynamic Kinetic Asymmetric Transformation (DYKAT)

Adrian Ortiz, Tamas Benkovics, Gregory L. Beutner et al. · Angewandte Chemie International Edition · 2015 · 57 citations

, , +11

Synthetic Access to the Chlorocyclopentane Cores of the Proposed Original and Revised Structures of Palau′amine

Michael Bultman, Jun Ma, David Y. Gin · Angewandte Chemie International Edition · 2008 · 45 citations · Full text

, , +11

Synthesis of the 6-Azaindole Containing HIV-1 Attachment Inhibitor Pro-Drug, BMS-663068

Ke Chen, Christina A. Risatti, Michael Bultman et al. · The Journal of Organic Chemistry · 2014 · 41 citations

, , +15

Rapid Development of a Commercial Process for Linrodostat, an Indoleamine 2,3-Dioxygenase (IDO) Inhibitor

Kenneth J. Fraunhoffer, Albert J. DelMonte, Gregory L. Beutner et al. · Organic Process Research & Development · 2019 · 38 citations

, , +10

Synthetic Access to the Chlorocyclopentane Cores of the Proposed Original and Revised Structures of Palau′amine

Michael Bultman, Jun Ma, David Y. Gin · Angewandte Chemie · 2008 · 16 citations

, , +11

1–5 of 8